By Dean Seal
Danaher reported higher earnings and revenue in the fourth quarter from gains in its life-sciences and biotechnology units, though it expects the top line to decline in the first quarter.
The manufacturing conglomerate posted a profit of $1.09 billion, or $1.49 a share, compared with $1.08 billion, or $1.45 a share, in the same quarter a year ago.
Stripping out one-time items, adjusted earnings were $2.14. Analysts surveyed by FactSet had been expecting $2.16 a share.
Sales rose 2% to $6.54 billion, above analyst projections for $6.44 billion, according to FactSet.
Revenue was up 6.3% in its biotechnology segment and 5.3% in its life-sciences division, offsetting a decline in the diagnostics business, its largest top line contributor.
Core revenue, which adjusts for foreign currency translation, acquisitions and divested product lines, was up 1%.
For the quarter ahead, Danaher expects core revenue to decline in the low-single-digit percentage range, but rise about 3% for the full year.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 29, 2025 06:29 ET (11:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。